Pasar al contenido principal

PROGRESION DE LA AMILOIDOSIS CARDIACA POR TRANSTIRETINA

PI20/01379

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Estudio, informe, memoria (Report)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy

  • Maestro, Alba|||0000-0003-1785-3125
  • Vela, Paula
  • De Frutos, Fernando|||0000-0003-4350-3217
  • Mora, Nerea
  • Pomares, Antonia
  • González-Vioque, Emiliano
  • Briceño, Ana
  • Cabrera-Borrego, Eva|||0000-0003-2997-2391
  • Cobo-Marcos, M.|||0000-0002-9026-061X
  • Dominguez, Fernando
  • Gonzalez-Lopez, Esther
  • Segovia, Javier|||0000-0002-4606-3416
  • Lara-Pezzi, Enrique
  • García-Pavía, Pablo|||0000-0002-5470-2257
Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a cause of heart failure in the elderly. Although wild-type transthyretin amyloidosis is the most frequent form of ATTR-CM found in the elderly, hereditary transthyretin amyloidosis (ATTRv) can also occur. We sought to determine the prevalence of ATTRv among elderly ATTR-CM patients, identify predictors of ATTRv and evaluate the clinical consequences of positive genetic testing in this population. Prevalence of ATTRv in elderly ATTR-CM patients (≥70 years) was assessed in a cohort of 300 consecutive ATTR-CM patients (median age 78 years at diagnosis, 82% ≥70 years, 16% female, 99% Caucasian). ATTRv was diagnosed in 35 (12%; 95% confidence interval [CI] 3.1-8.8) and 13 (5.3%; 95% CI 5.6-26.7) patients in the overall cohort and in those ≥70 years, respectively. Prevalence of ATTRv among elderly female patients with ATTR-CM was 13% (95% CI 2.1-23.5). Univariate analysis identified female sex (odds ratio [OR] 3.66; 95% CI 1.13-11.85; p = 0.03), black ancestry (OR 46.31; 95% CI 3.52-Inf; p = 0.005), eye symptoms (OR 6.64; 95% CI 1.20-36.73; p = 0.03) and polyneuropathy (OR 10.05; 95% CI 3.09-32.64; p < 0.001) as the only factors associated with ATTRv in this population. Diagnosis of ATTRv in elderly ATTR-CM patients allowed initiation of transthyretin-specific drug treatment in 5 individuals, genetic screening in 33 relatives from 13 families, and identification of 9 ATTRv asymptomatic carriers. Hereditary transthyretin amyloidosis is present in a substantial number of ATTR-CM patients aged ≥70 years. Identification of ATTRv in elderly patients with ATTR-CM has clinical meaningful therapeutic and diagnostic implications. These results support routine genetic testing in patients with ATTR-CM regardless of age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction

  • Amor-Salamanca, Almudena|||0000-0003-0420-8207
  • Santana Rodríguez, Alfredo
  • Rasoul, Hazhee|||0000-0002-4918-5304
  • Rodríguez-Palomares, José F.
  • Moldovan, Oana
  • Hey, Thomas Morris|||0000-0003-0262-7774
  • Gallego-Delgado, María|||0000-0003-0726-9646
  • Cuenca, David López|||0000-0003-3031-8768
  • de Castro Campos, Daniel|||0000-0003-1975-9132
  • Basurte-Elorz, María Teresa|||0000-0002-8689-0301
  • Macías-Ruiz, Rosa|||0000-0003-4686-5678
  • Fuentes Cañamero, María Eugenia|||0000-0003-1239-1275
  • Galvin, Joseph|||0000-0002-3617-8738
  • Bilbao Quesada, Raquel|||0000-0002-0505-9082
  • de la Higuera Romero, Luis
  • Trujillo-Quintero, Juan Pablo|||0000-0001-5901-9388
  • García-Cruz, Loida María
  • Cárdenas-Reyes, Ivonne
  • Jiménez-Jáimez, Juan|||0000-0001-5541-898X
  • García-Hernández, Soledad|||0000-0003-2547-685X
  • Valverde-Gómez, María|||0000-0002-4371-3620
  • Gómez-Díaz, Iria
  • Limeres Freire, Javier|||0000-0003-3644-9494
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Gimeno-Blanes, Juan R.|||0000-0001-5818-1754
  • Savattis, Konstantinos
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
Less than 40% of patients with dilated cardiomyopathy (DCM) have a pathogenic/likely pathogenic genetic variant identified. TBX20 has been linked to congenital heart defects; although an association with left ventricular noncompaction (LVNC) and DCM has been proposed, it is still considered a gene with limited evidence for these phenotypes. This study sought to investigate the association between the TBX20 truncating variant (TBX20tv) and DCM/LVNC. TBX20 was sequenced by next-generation sequencing in 7463 unrelated probands with a diagnosis of DCM or LVNC, 22 773 probands of an internal comparison group (hypertrophic cardiomyopathy, channelopathies, or aortic diseases), and 124 098 external controls (individuals from the gnomAD database). Enrichment of TBX20tv in DCM/LVNC was calculated, cosegregation was determined in selected families, and clinical characteristics and outcomes were analyzed in carriers. TBX20tv was enriched in DCM/LVNC (24/7463; 0.32%) compared with internal (1/22 773; 0.004%) and external comparison groups (4/124 098; 0.003%), with odds ratios of 73.23 (95% CI, 9.90-541.45; P <0.0001) and 99.76 (95% CI, 34.60-287.62; P <0.0001), respectively. TBX20tv was cosegregated with DCM/LVNC phenotype in 21 families for a combined logarythm of the odds score of 4.53 (strong linkage). Among 57 individuals with TBX20tv (49.1% men; mean age, 35.9±20.8 years), 41 (71.9%) exhibited DCM/LVNC, of whom 14 (34.1%) had also congenital heart defects. After a median follow-up of 6.9 (95% CI, 25-75:3.6-14.5) years, 9.7% of patients with DCM/LVNC had end-stage heart failure events and 4.8% experienced malignant ventricular arrhythmias. TBX20tv is associated with DCM/LVNC; congenital heart defect is also present in around one-third of cases. TBX20tv -associated DCM/LVNC is characterized by a nonaggressive phenotype, with a low incidence of major cardiovascular events. TBX20 should be considered a definitive gene for DCM and LVNC and routinely included in genetic testing panels for these phenotypes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis, a new endemic variant in Spain

  • De Frutos, Fernando|||0000-0003-4350-3217
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
  • Gómez-González, Cristina
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Aróstegui, Juan Ignacio|||0000-0003-4757-504X
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Barriales-Villa, Roberto|||0000-0002-6721-3487
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Gonzalez-Lopez, Esther
  • Ramil, Elvira
  • Galan, Lucia
  • González-Costello, José|||0000-0002-7437-3630
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Espinosa, Maria Angeles
  • García-Pavía, Pablo|||0000-0002-5470-2257
The p.Glu109Lys variant (Glu89Lys) is a rare cause of hereditary transthyretin amyloidosis (ATTRv) for which clinical spectrum remains unresolved. We sought to describe the clinical characteristics and outcomes of ATTR Glu89Lys amyloidosis and assess a potential founder effect in Spain. Patients with the p.Glu109Lys ATTRv variant from 14 families were recruited at 7 centres. Demographics, complementary tests and clinical course were analysed. Haplotype analysis was performed in 7 unrelated individuals. Thirty-eight individuals (13 probands, mean age 40.4 ± 13.1 years) were studied. After median follow-up of 5.1 years (IQR 1.7-9.6), 7 patients died and 7 required heart transplantation (median age at transplantation 50.5 years). Onset of cardiac and neurological manifestations occurred at a mean age of 48.4 and 46.8 years, respectively. Median survival from birth was 61.6 years and no individual survived beyond 65 years. Patients treated with disease-modifying therapies exhibited better prognosis (p < 0.001). Haplotype analysis revealed a common origin from an ancestor who lived ∼500 years ago in southeast Spain. Glu89Lys ATTRv is a TTR variant with a founder effect in Spain. It is associated with near complete penetrance, early onset and mixed cardiac and neurologic phenotype. Patients have poor prognosis, particularly if not treated with disease-modifying therapies.